FDA approved Zogenix Inc.’s Zohydro ER, finding that the single-entity extended-release hydrocodone product, the first to clear the agency, offers an important therapeutic option to treat pain.
A Schedule II controlled substance, Zohydro is indicated for the management of pain severe enough to require daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?